{
  "abstract": "Background: Chimeric antigen receptor T cells (CAR T) targeting CD19 can cure patients with aggressive B cell malignancies. Relapse due to CD19 loss and infections from B cell aplasia remain major causes of death after CD19 CAR T. We demonstrate that CD83 is a clinically relevant target for CAR T therapy in B cell malignancies, overcoming limitations of CD19 CAR T.\n\nMethods: We evaluate CD83 expression among B cell acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), and circulating healthy B cells, compared with CD19, CD20, and CD22. We test the activity of CD19 and CD83 CAR T against Raji and Nalm6 target cells using in vitro and in vivo preclinical models. Functional and immunophenotypic aspects of CD19 and CD83 CAR T are investigated to compare potency. Further, we evaluate CD19 and CD83 expression on B cell ALL after prior CD19-directed therapy, revealing a propensity for CD19 antigen loss. To simulate CD19 antigen loss, we test CD19 and CD83 CAR T against CD19 knock-out Nalm6 cells.\n\nResults: CD83 is expressed on B-cell ALL, MCL, and DLBCL, with negligible expression on circulating B cells and CLL. B cell ALL expresses CD83 at diagnosis and on relapse following CD19-directed therapy, when CD19 is decreased. CD83 CAR T kills B cell leukemia/lymphoma cell lines in vitro, providing efficacy after CD19 antigen loss. We show CD83 CAR T is effective as monotherapy in mice. Exploratory experiments suggest CD83 CAR T may offer enhanced efficacy when administered sequentially after CD19 CAR T.\n\nConclusions: Our preclinical evidence justifies further translational investigation of CD83 CAR T in B cell leukemia and lymphoma. The benefits of CD83 CAR T include a low risk for B cell aplasia and efficacy after exposure to CD19 CAR T.",
  "abstract_shown": true,
  "affiliations": [
    "Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA",
    "Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA",
    "University of Minnesota Twin Cities, Minneapolis, Minnesota, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 16,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Brian Christopher Betts",
      "orcid": "0000-0001-7643-2422"
    },
    {
      "affs": [
        1
      ],
      "name": "Constanza Savid-Frontera"
    },
    {
      "affs": [
        0
      ],
      "name": "Shannon McSain"
    },
    {
      "affs": [
        0
      ],
      "name": "Kelly Walton"
    },
    {
      "affs": [
        0
      ],
      "name": "Eliese Maybee"
    },
    {
      "affs": [
        0
      ],
      "name": "Nolan Beatty"
    },
    {
      "affs": [
        0
      ],
      "name": "Payal Goala"
    },
    {
      "affs": [
        0
      ],
      "name": "Duna Massillon"
    },
    {
      "affs": [
        0
      ],
      "name": "Isaac M Spiegel"
    },
    {
      "affs": [
        0
      ],
      "name": "Shernan G Holtan"
    },
    {
      "affs": [
        1
      ],
      "name": "Frederick L Locke"
    },
    {
      "affs": [
        2
      ],
      "name": "Anne Eaton"
    },
    {
      "affs": [
        2
      ],
      "name": "Michael A Linden"
    },
    {
      "affs": [
        0
      ],
      "name": "Meredith L Stone"
    },
    {
      "affs": [
        0
      ],
      "name": "Renier J Brentjens"
    },
    {
      "affs": [
        0
      ],
      "name": "Marco L Davila",
      "orcid": "0000-0002-6270-3065"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1aajeag6fwetf.bib",
  "cited_by": 0,
  "doi": "10.1136/jitc-2025-013670",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13711608/",
  "id": "1aajeag6fwetf",
  "issns": [
    "2051-1426"
  ],
  "landing_url": "https://doi.org/10.1136/jitc-2025-013670",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "1506"
    ],
    [
      "heading",
      "2436"
    ],
    [
      "heading",
      "Immune Cell Therapies and Immune Cell Engineering"
    ],
    [
      "heading",
      "Original Research"
    ],
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7223659488",
  "pdf_url": null,
  "pmcid": "PMC13711608",
  "pmid": "42933888",
  "published": "2026-10-26",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/1aajeag6fwetf.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:22:21Z",
      "native_id": "PMC13711608",
      "source": "pmc",
      "url": "https://doi.org/10.1136/jitc-2025-013670"
    },
    {
      "first_seen": "2026-10-31T14:21:45Z",
      "native_id": "2593a7435a7e4215bebfd1a53912f00c",
      "source": "doaj",
      "url": "https://doi.org/10.1136/jitc-2025-013670"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|CAR-T cell therapy research",
      "subfield": "oncology"
    }
  ],
  "title": "CD83 CAR T provides an alternative strategy to CD19-targeting in B cell malignancies",
  "title_text": "CD83 CAR T provides an alternative strategy to CD19-targeting in B cell malignancies",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T14:21:45Z",
  "url": "https://research.draconitic.com/paper/1aajeag6fwetf",
  "venue": "Journal for Immunotherapy of Cancer",
  "versions": []
}